BSD Medical Ships BSD-2000/3D/MR Image Guided Hyperthermia System for Installation at Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has shipped a BSD-2000/3D/MR Image Guided Hyperthermia System (BSD-2000/3D/MR) to Dr. Sennewald Medizintechnik GmbH. The BSD-2000/3D/MR will be installed at the Erasmus MC Cancer Institute (Erasmus) - Daniel den Hoed Cancer Center. The BSD-2000/3D/MR system integrates a BSD-2000/3D Hyperthermia System with Magnetic Resonance (MR) imaging to deliver targeted image guided hyperthermia therapy, while simultaneously providing non-invasive imaging of the diseased tissue as well as the surrounding healthy tissue. The magnetic resonance images are color graded to show temperature changes in the treatment area during hyperthermia therapy.

The Erasmus system will be the sixth BSD-2000 System with integrated MR capability purchased by prestigious educational institutions in Europe. Similar systems have also been installed at the Munich Grosshadern UMS, Berlin Charité UMS, Erlangen UMS, Tuebingen UMS, and Duesseldorf UMS, all in Germany.

About Erasmus MC Cancer Institute

Erasmus MC Cancer Institute is in the top 10 most prestigious medical centers in Europe and the largest academic teaching hospital in The Netherlands. Erasmus MC Cancer Institute - Daniel den Hoed Cancer Center, is internationally recognized for its dedicated patient care and innovative and groundbreaking medical research in oncology. The Hyperthermia Unit of the Department of Radiation Oncology at Erasmus MC is one of the leading hyperthermia treatment centers in the world, and the department operates 14 linear accelerators with state-of-the-art technology. This is the second BSD-2000 Hyperthermia System purchased by Erasmus MC. The Erasmus MC hyperthermia unit already operates a BSD 2000/3D system for routine pelvic hyperthermia patient treatments as well as an array of other hyperthermia systems for the treatment of local disease. Erasmus MC has been instrumental in the development of hyperthermia from a promising field of research to an accepted therapy for the treatment of cancer. Erasmus MC was also instrumental in assisting BSD in obtaining FDA Humanitarian Device Exemption approval of the BSD 2000 through its Phase III, multicenter, clinical study on hyperthermia combined with radiotherapy compared with radiotherapy alone, which was published in The Lancet. one of the most prestigious scientific medical journals in the world with an impact factor of 39·06.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU. The BSD-2000/3D/MR has received CE Marking approval.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.